Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5743 USD | -2.94% | +1.75% | +5.71% |
Financials (USD)
Sales 2024 * | 38.83M | Sales 2025 * | 70.15M | Capitalization | 119M |
---|---|---|---|---|---|
Net income 2024 * | -107M | Net income 2025 * | -46M | EV / Sales 2024 * | 4.12 x |
Net Debt 2024 * | 40.79M | Net Debt 2025 * | 129M | EV / Sales 2025 * | 3.54 x |
P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
-2.59
x | Employees | 405 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.89% |
Latest transcript on Sangamo Therapeutics, Inc.
1 day | -2.94% | ||
1 week | +1.75% | ||
Current month | +1.75% | ||
1 month | +14.31% | ||
3 months | -36.62% | ||
6 months | +18.41% | ||
Current year | +5.71% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
Director of Finance/CFO | 45 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 59 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.66% | 2 M€ | -25.75% | ||
0.49% | 15 M€ | -3.61% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.5743 | -2.94% | 1,152,582 |
24-06-06 | 0.5917 | +1.08% | 1,194,219 |
24-06-05 | 0.5854 | +3.14% | 1,272,633 |
24-06-04 | 0.5676 | -2.61% | 1,560,916 |
24-06-03 | 0.5828 | +3.26% | 1,306,394 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.71% | 119M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- SGMO Stock